Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • ABCDE@lemmy.world
    link
    fedilink
    arrow-up
    48
    arrow-down
    2
    ·
    edit-2
    9 months ago

    …no? Because that didn’t happen. “The” vaccine was multiple different ones, including some made in China and the UK.